Atezolizumab

Atezolizumab is a monoclonal antibody medication used in cancer immunotherapy. It is a checkpoint inhibitor designed to target the programmed death-ligand 1 (PD-L1) protein. Developed by Genentech, a member of the Roche Group, it is marketed under the brand name Tecentriq. The drug has received approval from regulatory bodies like the U.S. Food and Drug Administration and the European Medicines Agency for treating several advanced cancers.

Medical uses

Atezolizumab is approved for the treatment of various advanced or metastatic malignancies. Its indications include urothelial carcinoma, specifically for patients ineligible for cisplatin-containing chemotherapy. In non-small cell lung cancer, it is used both as a monotherapy and in combination with chemotherapies like carboplatin and paclitaxel, as well as with the antiangiogenic agent bevacizumab. For triple-negative breast cancer, it is combined with nab-paclitaxel for patients whose tumors express PD-L1. Additional approvals cover its use in hepatocellular carcinoma in combination with bevacizumab, and for alveolar soft part sarcoma. Clinical trials, such as those presented at the American Society of Clinical Oncology annual meeting, continue to explore its efficacy in other cancers like renal cell carcinoma and small cell lung cancer.

Adverse effects

Common adverse reactions associated with atezolizumab include fatigue, decreased appetite, nausea, and cough. As with other immune checkpoint inhibitors, it can cause immune-mediated adverse effects due to the enhancement of T cell activity. These serious reactions may include pneumonitis, colitis, hepatitis, and endocrinopathies such as hypothyroidism and adrenal insufficiency. Infusion-related reactions and severe skin conditions like rash and Stevens-Johnson syndrome have also been reported. Management typically involves corticosteroids, such as prednisone, and may require treatment interruption or discontinuation as per guidelines from the National Comprehensive Cancer Network.

Mechanism of action

Atezolizumab is a humanized immunoglobulin G1 monoclonal antibody that functions as a checkpoint inhibitor. It binds specifically to programmed death-ligand 1 (PD-L1), a protein expressed on the surface of some tumor cells and tumor-infiltrating immune cells. By binding to PD-L1, atezolizumab blocks its interaction with the programmed cell death protein 1 (PD-1) and B7.1 receptors on T cells. This blockade prevents the PD-L1-mediated inhibitory signal, thereby restoring the cytotoxic activity of T cells against tumor cells. This mechanism enhances the body's immune response to cancer, a principle central to cancer immunotherapy pioneered by researchers like James P. Allison.

History

The development of atezolizumab originated from research into the PD-1/PD-L1 pathway by scientists at Genentech. The drug, initially known by its code MPDL3280A, entered clinical development in the early 2010s. It received its first accelerated approval from the U.S. Food and Drug Administration in May 2016 for advanced urothelial carcinoma, based on results from the IMvigor210 trial. Subsequent approvals followed for non-small cell lung cancer based on the OAK and IMpower150 studies, and for triple-negative breast cancer from the IMpassion130 trial. The European Medicines Agency granted its first marketing authorization in 2017. Ongoing research is conducted through collaborations with institutions like the National Cancer Institute.

Society and culture

Atezolizumab, sold as Tecentriq, has had a significant impact on oncology practice and healthcare economics. Its development and pricing have been subjects of discussion within organizations like the National Institute for Health and Care Excellence in the United Kingdom and the Institute for Clinical and Economic Review in the United States. The drug has been featured in media reports by outlets such as The New York Times highlighting advances in immunotherapy. Patient access programs have been established by Roche in various countries. The story of its development contributes to the broader narrative of cancer immunotherapy, a field recognized by the Nobel Prize in Physiology or Medicine awarded to James P. Allison and Tasuku Honjo.

Category:Monoclonal antibodies Category:Antineoplastic drugs Category:Immunotherapy